ABSTRACT
In chronic disease epidemiology, the investigation of disease etiology has largely focused on one endpoint, and the progression of chronic disease as a multi-state process is understudied, representing a knowledge gap. Most existing multi-state regression models require Markov assumption and are unsuitable to describe the course of chronic disease progression that is largely non-memoryless. We propose a new non-Markov framework that allows past states to affect the transition rates of current states, and the key innovation is the conversion of a non-Markov to Markov process by conditioning on past disease history to divide disease states into substates. Specifically, we apply cause-specific Cox models, including past states as covariates, to obtain transition rates of substates, which were used to estimate transition probabilities using the discrete-time Aalen-Johansen estimator. In simulation study, the non-Markov model generated higher coverage rates of transition rates compared to Markov models, particularly for non-Markov process (By applying non-Markov and Markov models, coverage rates were 91% and 88% for Markov process with exponential distribution, 52% and 43% for Markov process with Weibull distribution, 92% and 49% for non-Markov process with exponential distribution, and 59% and 23% for non-Markov process with Weibull distribution). We applied our model to describe the course of coronary heart disease (CHD) progression, where CHD was modeled in healthy, at-risk, CHD, heart failure, and mortality states. In summary, the significance of our framework lies in the fact that transition parameters between disease sub-states may provide a more accurate description of disease course than Markov regression models and shed light on new mechanistic insight into chronic disease. Our method has the potential for wide application in chronic disease epidemiology.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The project described was supported by National Institutes of Health and National Center for Advancing Translational Sciences (NCATS), through Grant Award Number R21 HG012365 and UM1TR004406.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We obtained ARIC data through BioLINCC, an open repository created by NHLBI, with the IRB deemed exempt by the University of North Carolina (UNC)-Chapel Hill Review Board.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
--Simulation study results. --Updated tables and figures in the application study.
DATA AVAILABILITY STATEMENT
The R code for the non-Markov framework is available at the GitHub repository (https://github.com/mingding-hsph/A-non-Markov-regression-framework).